Cargando…
Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer
It is estimated that pancreatic cancer will be the second leading cause of cancer-related deaths globally by 2030, highlighting the ongoing lack of effective treatment options for this devastating condition. There is a lack of reliable prognostic or predictive markers in pancreatic cancer to guide m...
Autores principales: | Lee, Belinda, Gibbs, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616860/ https://www.ncbi.nlm.nih.gov/pubmed/31035449 http://dx.doi.org/10.3390/jpm9020020 |
Ejemplares similares
-
Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force
por: Butterfield, Lisa H, et al.
Publicado: (2010) -
Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers
por: Venetis, Konstantinos, et al.
Publicado: (2020) -
The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies
por: Annapragada, Ananth, et al.
Publicado: (2023) -
Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC
por: De Marchi, Pedro, et al.
Publicado: (2023) -
Immune landscape and biomarkers for immuno-oncology in colorectal cancers
por: Bae, Jeong Mo, et al.
Publicado: (2020)